Literature DB >> 29102496

Plasma inducible degrader of the LDLR, soluble low-density lipoprotein receptor, and proprotein convertase subtilisin/kexin type 9 levels as potential biomarkers of familial hypercholesterolemia in children.

Josefa Girona1, Cèlia Rodríguez-Borjabad1, Daiana Ibarretxe1, Mercedes Heras1, Nuria Amigo2, Albert Feliu3, Luis Masana4, Nuria Plana1.   

Abstract

BACKGROUND: Familial hypercholesterolemia (FH) in children is under-detected. Plasma biomarkers associated with low-density lipoprotein receptor (LDLR) function could help identifying FH children.
OBJECTIVES: We aim to assess the clinical value of inducible degrader of the LDLR (IDOL), soluble LDLR (sLDLR), and proprotein convertase subtilisin/kexin type 9 (PCSK9) plasma concentrations in children with FH compared with control children (CCh).
METHODS: This was a cross-sectional study performed in a Lipid Unit from a University hospital. The participants were 177 children distributed into FH (n = 77) and CCh (n = 100). Main outcomes were changes in IDOL, sLDLR, and PCSK9 plasma concentrations between children groups; secondary outcomes were the association between IDOL, sLDLR, and PCSK9 and lipid profile determined by 2-dimensional nuclear magnetic resonance.
RESULTS: The IDOL levels were higher in FH compared with CCh (P = .007). The PCSK9 levels were elevated in FH (P < .001). The sLDLR levels had no significant differences between groups. IDOL was significantly positively associated to total and LDL cholesterol and ApoB100 but not to LDL particle number. However, a robust correlation with Lp(a) (P = .001) was observed. PCSK9 had the strongest correlation with LDL-associated parameters including particle number. sLDLR was associated with triglyceride levels (P < .001) and triglyceride-rich particles and inversely to LDL size.
CONCLUSIONS: The IDOL and PCSK9 plasma levels are significantly higher in FH children. Interestingly, sLDLR was associated with atherogenic dyslipidemia components. IDOL concentrations show a robust association with Lp(a) levels. To study the role of plasma biomarkers associated with LDLR expression in FH is warranted.
Copyright © 2017 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  2D-1H-NMR; Children; Familial hypercholesterolemia; IDOL; LDL; LDLR; Lp(a); PCSK9; Triglyceride

Mesh:

Substances:

Year:  2017        PMID: 29102496     DOI: 10.1016/j.jacl.2017.10.003

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  4 in total

1.  Effects of statins on the inducible degrader of low-density lipoprotein receptor in familial hypercholesterolemia.

Authors:  Melody Lok-Yi Chan; Sammy Wing-Ming Shiu; Ching-Lung Cheung; Anskar Yu-Hung Leung; Kathryn Choon-Beng Tan
Journal:  Endocr Connect       Date:  2022-06-15       Impact factor: 3.221

2.  The enigma of soluble LDLR: could inflammation be the key?

Authors:  Majambu Mbikay; Janice Mayne; Michel Chrétien
Journal:  Lipids Health Dis       Date:  2020-02-03       Impact factor: 3.876

3.  Serum PCSK9 Correlates with PTX3 and Apolipoproteins B, A1, and C3 Concentrations in Patients with Type 2 Diabetes.

Authors:  Małgorzata Waluś-Miarka; Maria Kapusta; Przemysław Miarka; Ewa Kawalec; Barbara Idzior-Waluś
Journal:  Cardiovasc Ther       Date:  2021-12-21       Impact factor: 3.023

4.  Platycodin D enhances LDLR expression and LDL uptake via down-regulation of IDOL mRNA in hepatic cells.

Authors:  Yu-Jeong Choi; Sol Ji Lee; Hyo In Kim; Hee Jung Lee; So Jung Kang; Tai Young Kim; Chunhoo Cheon; Seong-Gyu Ko
Journal:  Sci Rep       Date:  2020-11-16       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.